Clinical features of post-hepatitis B liver cirrhosis associated with diabetes mellitus
-
摘要: 目的研究乙型肝炎肝硬化合并糖尿病不同于2型糖尿病的临床特点。方法分别对乙型肝炎肝硬化合并糖尿病(肝糖组)112例和2型糖尿病(糖尿病组)106例患者进行口服葡萄糖耐量试验(OGTT)、胰岛素释放试验(IRT)、C肽释放试验(CRT),同时检测胰高血糖素(Glu),并分别计算胰岛素抵抗指数HOMA-IR、β细胞功能指数(HOMA-β,MBCI)等,分析比较两组之间的差异。结果在OGTT各时间点(0、30、60、120、180 min),肝糖组的血糖均显著低于糖尿病组(P<0.001)。两组空腹时胰岛素含量无明显差异,而肝糖组在餐后30、60、120、180 min的胰岛素含量均显著高于糖尿病组(P<0.001)。在餐后60、120、180 min,肝糖组C肽值明显高于糖尿病组(P<0.01、P<0.01和P<0.05)。与糖尿病组相比,肝糖组的Glu水平明显升高(P<0.05),异常升高人数显著增多(P<0.001)。两组间发生血糖低于正常情况有明显差异(P<0.01)。肝糖组的HOMA-IR指数较糖尿病组显著低下(P<0.01)。结...Abstract: Objective To study the clinical features of post-hepatitis B liver cirrhosis (LC) that are associated with diabetes mellitus (LCDM) and distinctive from type 2 diabetes mellitus (T2DM) without HBV infection or LC.Methods One-hundred-and-six post-hepatitis B LCDM patients and 112 T2DM patients were analyzed.All patients underwent oral glucose tolerance test (OGTT) , insulin release test (IRT) , C-peptide release test (CRT) , and glucagon (Glu) test.The homeostasis model assessment of insulin resistance (HOMA-IR) index, HOMA beta cell function (HOMA-β) , and modified beta cell function index (MBCI) were calculated.Between group differences were statistically analyzed.ResultsThe OGTT glucose levels were consistently significantly lower in LCDM than in T2DM (P<0.001) .Some insulin levels (30, 60, 120, 180min) were significantly higher in LCDM (P<0.001) .The fasting and 30 min insulin levels were not significantly different.The postprandial C-peptide levels (60, 120, 180min) were significantly higher in LCDM (P<0.05) .Glu was much higher in LCDM (P<0.05) , and the percentage of patients with abnormally elevated Glu was also significantly different between the two groups (P<0.001) .Eighty-three percent of LCDM patients had normal fasting glucose, and their diabetes mellitus was diagnosed by abnormal postprandial glucose.The percentage of patients with abnormal fasting glucose was significantly lower in the LCDM group (P<0.001) .Lower than normal glucose levels were much more prevalent in the T2DM group (P<0.01) .The HOMA-IR was lower in LCDM (P<0.01) .The HOMA-β and MBCI were similar between the two groups (P>0.05) .Conclusion Post-hepatitis B LCDM has several clinical features that are distinctive from T2DM, including postprandial glucose, OGTT curve, IRT curve, CRT curve, Glu, insulin resistance index, and lower fasting glucose.The features of insulin resistance and abnormally increased Glu may be one of the main causes of DM in HBV-related cirrhotic patients.
-
Key words:
- liver cirrhosis /
- diabetes mellitus
-
[1]Moscatiello S, Manini R, Marchesini G.Diabetes and liver dis-ease:an ominous association[J].Nutr Metab Cardiovasc Dis, 2007, 17 (1) :63-70. [2]Harrison SA.Liver disease in patients with diabetes mellitus[J].J Clin Gastroenterol, 2006, 40 (1) :68-76. [3]Amarapurkar D, Das HS.Chronic liver disease in diabetes mellitus[J].Trop Gastroenterol, 2002, 23 (1) :3-5. [4]许曼音, 陆广华, 陈名道.糖尿病学[M].第二版, 上海:上海科学技术出版社, 2010:622-628. [5]中华医学会传染病与寄生虫病学分会、肝病学分会联合修订.病毒性肝炎防治方案[J].中华内科杂志, 2001, 40 (1) :62-68. [6]World Health Organisation.Definition, diagnosis, and classification of diabetes mellitus and its complications.Report of a WHO consultation.Part1:diagnosis and classification of diabetes mellitus[R].Geneva:World Health Organisation, 1999. [7]Matthews DR.Homeostasis model assessment:insulin resistance and beta-cel1function from fasting plasma glucose and insulin concentra-tion in man[J].Diabetologia, 1985, 28:42. [8]李光伟.胰岛β细胞功能评估[J].国外医学内分泌学分册, 2001, 21 (5) :225-227. [9]Marchesini G, Ronchi M, Forlani G, et al.Cardiovascular disease in cir-rhosis[J].Am J Gastroenterol, 1999, 94 (3) :655-62.. [10]Holstein A, Hinze S, Thiessen E, et al.Clinical implications of hepatogenous diabetes in liver cirrhosis[J].J-Gastroenterol-Hepatol, 2002, 17 (6) :677-681. [11]Petrides AS, Vogt C, Schulze Berge D, et al.Pathogenesis of glu-cose intolerance and diabetes mellitus in cirrhosis[J].Hepatology, 1994, 19 (3) :616-627. [12]姜庆五.流行病学[M].北京:科学出版社, 2003:325-338. [13]丁惠国, 汪俊韬, 于中麟.肝硬化的抗胰岛素性[J].中华肝脏病杂志, 1996, 4 (1) :56-57. [14]王妲, 杨永年.糖尿病现代治疗学[M].北京:科学出版社.2005:193. [15]吴彩兰, 宋眷青.肝硬化患者糖耐量、胰岛素及C肽的变化[J].天津医药, 2004, 32 (5) :300-301. [16]杨周榕, 何品玉, 王丽纳.胰岛素、C肽释放试验及血糖联合测定的临床价值[J].福建医药杂志, 2003, 25 (3) :104-106. [17]韩致毅, 周黎黎.肝源性糖尿病患者胰岛β细胞功能和胰岛素抵抗及临床意义[J].临床和实验医学杂志, 2011, 10 (5) :330-332. [18]吴志勇, 黄安, 邝耀麟, 等.鼠肝硬变形成中和门腔分流术后生长抑素和胰高血糖素变化的动态观察[J].中华消化杂志, 1990, 10 (5) :251-254. [19]Smith L, Sherlock GS, Faber OK.Effects of spontaneous portal-systemic shunting on insulin metabolism[J].Gastroenterology, 1979, 76 (4) :685-690. [20]Shurberg JL, Resnick RH, Koff RS, et al.Serum lipids, insulin, and glucagon after porto-caval shunt in cirrhosis[J].Gastroenter-ology, 1977, 72 (2) :301-304. [21]Sherwin R, Joshi P, Hendler R, et al.Hyperglucagonaemia in Lae-nnec’s cirrhosis.The role of portal-systemic shunting[J].N Engl J Med, 1974, 290 (5) :239-242. [22]Sherwin R, Fisher M, Bessoff J, et al.Hyperglucagonemia in cir-rhosis:altered secretion and sensitivity to glucagon[J].Gastroen-terology, 1978, 74 (6) :1224-1228. [23] Haffner SM, Kennedy E, Gonzalez C, et al.A prospective analysis of the HOMA model.The Mexico City Diabetes Study[J].Diabetes Care, 1996, 19 (10) :1138-1141. [24]李光伟.胰岛素抵抗评估及其临床应用[J].中华老年多器官疾病杂志, 2004, 3 (1) :11-12. [25]叶山东, 朱禧星.临床糖尿病学[M].安徽:安徽科学技术出版社出版, 2005:274. [26]武阳丰, 谢高强, 李莹, 等.中国部分中年人群糖尿病患病率、知晓率、治疗率及控制率现况调查[J].中华流行病学杂志, 2005, 26 (8) :564-568. [27]梁扩寰, 李绍白.肝脏病学[M].北京:人民卫生出版社, 2003:822.
本文二维码
计量
- 文章访问数: 2977
- HTML全文浏览量: 18
- PDF下载量: 746
- 被引次数: 0